Mitochondrion

A NEW STUDY SUGGESTS ENERGY4LIFE'S BIOENERGETIC WEARABLE DEVICE MAY HAVE POSITIVE EFFECTS ON CELLULAR MEMBRANE

Retrieved on: 
Wednesday, March 22, 2023

PARK CITY, Utah, March 22, 2023 /PRNewswire/ -- A recent study by researchers at the University of California at San Diego, found that a bioenergetic wearable device delivering biological information to the body using photons, has positive effects on the physiology of live cell cultures. This study has found these results may lead to improved energy levels and sleep quality, reduce stress, and help people better manage their emotions.

Key Points: 
  • This study has found these results may lead to improved energy levels and sleep quality, reduce stress, and help people better manage their emotions.
  • A cutting-edge technology, developed and created by Energy4Life, bioenergetic wearable devices use digitized biological information to help restore the body's energy.
  • "Our bioenergetic wearables are designed to communicate directly to the body, thus triggering its self-repair system", said Harry Massey founder and CEO of Energy4Life.
  • This equipment includes the NES Health miHealth device and the GEM wearable, a new device slated for release in late 2023 by Massey's newest company, Energy4Life.

MitoQ Wins Award for Best New Heart Health Supplement of 2023

Retrieved on: 
Tuesday, March 21, 2023

Coenzyme Q10 helps to make energy in the mitochondria -- small structures in the cell that transform food and oxygen into chemical energy, fueling cellular health and regeneration. CoQ10 is also a powerful antioxidant that helps prevent damage to cell membranes and DNA caused by free radicals (highly reactive fragments of oxygen and nitrogen emitted by mitochondria in the process of creating biochemical energy). MitoQ, a patented molecule, is a significantly more bioavailable variation on the CoQ10 theme.

Key Points: 
  • Smart Drugs and Supplements Magazine has awarded MitoQ its highest honors for the company's offering of the most innovative new heart health supplement in the 2023 consumer marketplace.
  • NEW YORK, March 21, 2023 /PRNewswire/ -- Smart Drugs and Supplements Magazine announced today that it has awarded its Best New Heart Health Supplement Award to New Zealand-based MitoQ for its breakthrough technology in cell health, affording demonstrated heart health and anti-aging support benefits.
  • The award is based on information provided by third-party clinical studies and the results of product research conducted by the magazine.
  • Healthcare applications to promote heart health are expected to drive market statistics over the forecast period, increasing demand for MitoQ.

Results from the first clinical pilot study using maternal spindle transfer indicate that the technique may have value as a treatment for challenging types of infertility and reveal potential limitations when the method is used for avoidance of mitochondr

Retrieved on: 
Friday, March 17, 2023

The exploratory study provides the first insights into safety and efficacy of maternal spindle transfer in humans, when applied in a context of infertility treatment.

Key Points: 
  • The exploratory study provides the first insights into safety and efficacy of maternal spindle transfer in humans, when applied in a context of infertility treatment.
  • Maternal spindle transfer is an advanced laboratory technique that belongs to the family of methods known collectively as mitochondrial replacement therapies (MRTs).
  • The research team aimed to explore, for the first time, the clinical feasibility of the maternal spindle transfer technique in a context of infertility treatment.
  • A definitive assessment of the clinical value of the technique must await future larger, controlled and randomized trials.

Results from the first clinical pilot study using maternal spindle transfer indicate that the technique may have value as a treatment for challenging types of infertility and reveal potential limitations when the method is used for avoidance of mitochondr

Retrieved on: 
Friday, March 17, 2023

The exploratory study provides the first insights into safety and efficacy of maternal spindle transfer in humans, when applied in a context of infertility treatment.

Key Points: 
  • The exploratory study provides the first insights into safety and efficacy of maternal spindle transfer in humans, when applied in a context of infertility treatment.
  • Maternal spindle transfer is an advanced laboratory technique that belongs to the family of methods known collectively as mitochondrial replacement therapies (MRTs).
  • The research team aimed to explore, for the first time, the clinical feasibility of the maternal spindle transfer technique in a context of infertility treatment.
  • A definitive assessment of the clinical value of the technique must await future larger, controlled and randomized trials.

Feinstein Institutes’ Study Discovers That Mitochondrial Transplantation Improves Survival and Outcomes After Cardiac Arrest

Retrieved on: 
Thursday, March 16, 2023

Through a series of studies, researchers at The Feinstein Institutes for Medical Research have shown that mitochondria transplantation (MTx), delivering new mitochondria to critical tissues, can improve survival and neurological outcomes after cardiac arrest.

Key Points: 
  • Through a series of studies, researchers at The Feinstein Institutes for Medical Research have shown that mitochondria transplantation (MTx), delivering new mitochondria to critical tissues, can improve survival and neurological outcomes after cardiac arrest.
  • View the full release here: https://www.businesswire.com/news/home/20230316005460/en/
    Dr. Lance Becker led the new research on mitochondria transplantation.
  • “Mitochondria transplantation is an untapped area of research and therapy that could lead to clinical benefits to restore much-needed energy.
  • The results showed that the animals receiving fresh mitochondria infusion improved neurological function and survival, from 55 percent to 91 percent, after cardiac arrest and resuscitation.

Prime Medicine Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 9, 2023

CAMBRIDGE, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2022.

Key Points: 
  • “In 2022, we made important progress in our efforts to build Prime Medicine and demonstrate the promise of Prime Editors as a potentially best-in-class genetic medicine approach,” said Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine.
  • Prime Medicine expects the following activities and next steps to drive the Prime Editing platform forward:
    Initiate investigational new drug (IND)-enabling studies of PM359 for the treatment of CGD in 2023.
  • Maximize Prime Editing’s broad therapeutic potential and create value through strategic business development that extends the reach and impact of Prime Editing to areas beyond Prime Medicine’s current areas of focus.
  • Fourth Quarter and Full Year 2022 Financial Results:
    Research and Development (R&D) Expenses: R&D expenses were $29.1 million for the fourth quarter of 2022 and $86.7 million for the year ended December 31, 2022, as compared to $52.9 million for the fourth quarter of 2021 and $70.6 million for the year ended December 31, 2021.

Michael F. Price Memorial Grant from DeGregorio Family Foundation Awarded to Improve Survival Rates in Esophageal Cancer

Retrieved on: 
Tuesday, March 7, 2023

The Grant is named in memory of Michael F. Price, the noted value investor and philanthropist, who was an early supporter of the Foundation.

Key Points: 
  • The Grant is named in memory of Michael F. Price, the noted value investor and philanthropist, who was an early supporter of the Foundation.
  • The ultimate goal is to rapidly determine the best approach for treating each individual patient with esophageal cancer.
  • The DeGregorio Family Foundation, founded in 2006 after a 10th member of the DeGregorio family died of stomach cancer, has raised almost $8 million to fund innovative research focused on curing gastroesophageal cancers.
  • "Esophageal adenocarcinoma is the most common subtype of esophageal cancer in the U.S., and it is one of the fastest-growing cancers today," concluded Lynn DeGregorio, President and Founder.

Unicycive to Highlight Potential of UNI-494 to Restore Mitochondrial Function and Reduce Oxidative Stress at Two Upcoming Medical and Scientific Meetings

Retrieved on: 
Monday, February 27, 2023

LOS ALTOS, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the potential of UNI-494, the Company’s proprietary drug that selectively binds to the SUR2B subunit of the mitochondrial KATP channel, will be the focus of several presentations at two upcoming medical and scientific meetings in March 2023.

Key Points: 
  • Shalabh Gupta, M.D., Chief Executive Officer of Unicycive, will lead a discussion on UNI-494 at the upcoming 5th Annual Chronic Kidney Disease Drug Development Summit taking place in Boston, MA from March 7-9, 2023.
  • Two abstracts were accepted for presentation at the 28th International Conference on Critical Care in Nephrology: the Acute Kidney Injury & CRRT Conference taking place in San Diego, CA from March 29- April 1, 2023.
  • “We are studying UNI-494 in Phase 1 clinical trial in the United Kingdom (UK).
  • We also plan to file a corresponding Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) in 2023 for a Phase 2 proof-of-concept trial in acute kidney injury (AKI) patients.”

Rejuvenating Fertility Center Named First Fertility Clinic in the US with No Age or Weight Cutoff

Retrieved on: 
Wednesday, February 15, 2023

New York, New York--(Newsfile Corp. - February 15, 2023) - New England based fertility clinic Rejuvenating Fertility Clinic (RFC) has been named the first fertility clinic in the United States that imposes no cutoffs for patients based upon age or weight.

Key Points: 
  • New York, New York--(Newsfile Corp. - February 15, 2023) - New England based fertility clinic Rejuvenating Fertility Clinic (RFC) has been named the first fertility clinic in the United States that imposes no cutoffs for patients based upon age or weight.
  • "We have no age or weight restrictions for women undergoing IVF, egg freezing, or our other many services."
  • He adds that RFC has resources for patients who have been rejected by other fertility clinics based on their age or weight.
  • Rejuvenating Fertility Clinic is the first IVF Center in the Northeast to offer non-conventional, holistic, and organic fertility methods.

NRG Therapeutics Awarded Second $500K Grant from The Michael J. Fox Foundation to Further Progress Parkinson’s Programme

Retrieved on: 
Wednesday, February 22, 2023

STEVENAGE, United Kingdom, Feb. 22, 2023 (GLOBE NEWSWIRE) -- NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that it has been awarded a second $500,000 grant from The Michael J.

Key Points: 
  • STEVENAGE, United Kingdom, Feb. 22, 2023 (GLOBE NEWSWIRE) -- NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that it has been awarded a second $500,000 grant from The Michael J.
  • Fox Foundation for Parkinson’s Research (MJFF), to support its lead drug discovery programme and the development of a novel treatment for Parkinson’s.
  • NRG Therapeutics is applying breakthrough science in the field of mitochondrial biology to develop first-in-class treatments for Parkinson’s.
  • Having met the goals of the grant it received from MJFF in 2021 , this second grant will support experiments to validate a novel mitochondrial drug target for Parkinson’s.